Skip to main content

Pasternak Andy's Form 4 filing

Horizon Therapeutics Public Ltd CoHZNP · filed Dec 14, 2022

Accession no.
0001209191-22-061269
Filed
Dec 14, 2022
Trade date
Dec 13, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $3.40M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Pasternak AndyCIK 0001792746Officer (EVP, Chief Strategy Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Dec 13, 2022Ordinary SharesMOption exerciseAcquired+23,251$29.52+$686,369.5264,216Direct
Dec 13, 2022Ordinary SharesSSaleDisposed−23,251$112.61F1−$2,618,295.1140,965Direct
Dec 13, 2022Ordinary SharesSSaleDisposed−6,918$112.60F2−$778,966.834,047Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Dec 13, 2022Ordinary SharesMOption exerciseDisposed−23,251$0.00$00Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.555 to $112.6701 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

F2

The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.5950 to $112.60 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)